StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.1
  1. Startseite
  2. /Verbindung

Dasabuvir

HCID 56640146
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
1132935-63-7
Standard-SMILES
COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C
InChIKey
NBRBXGKOEOGLOI-UHFFFAOYSA-N
Summenformel
C26H27N3O5S
Durchschnittliche Molmasse
493,6 g/mol
Monoisotopische Masse
493,16714196

Überblick

Dasabuvir is a member of the class of pyrimidone, which is (as the monohydrate of its sodium salt) in combination with ombitasvir, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. It has a role as an antiviral drug and a nonnucleoside hepatitis C virus polymerase inhibitor. It is a member of naphthalenes, a sulfonamide, an aromatic ether and a pyrimidone. It is functionally related to a uracil.

Namen und Bezeichner

Bevorzugter Name
Dasabuvir
IUPAC
N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide
Englischer Name
ABT-333
Summenformel
C26H27N3O5S
Molmasse
493.57

Namen und Synonyme

Dasabuvir1132935-63-7ABT-333ABT333exvieraDE54EQW8T1N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamideABT 333CHEBI:85182DTXSID301025953Methanesulfonamide, N-(6-(5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl)-2-naphthalenyl)-N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide
Weitere Namen anzeigen
CS-2000ABT-333/DasabuvirDasabuvir (ABT-333)Dasabuvir-13C 15N2 D3Dasabuvir, 10 mM in DMSON-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]-2-naphthyl}methanesulfonamideN-{6-[5-(2,4-Dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-2-methoxy-3-(2-methyl-2-propanyl)phenyl]-2-naphthyl}methanesulfonamide
N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamidedasabuvirumN-(6-(3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamideRefChem:585200J05AP09DTXCID901510205805-439-9N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
4,3
Polarare Oberfläche (TPSA)
113 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
6
Schwere Atome
35
Formalladung
0
Komplexität
938

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsBreast Feeding; Lactation; Milk, Human; Antiviral Agents

Physikochemische Eigenschaften

Schmelzpunkt
192 oC · >192oC (dec.)
Dichte
1.317 · 1.317±0.06 g/cm3(Predicted)
storage temp.
-20 °C · Hygroscopic, -20°C Freezer, Under inert atmosphere
Löslichkeit
Chloroform (Slightly, Heated), DMSO (Slightly), Methanol (Slightly, Heated)
Aggregatzustand
Solid
pka
8.52 · 8.52±0.30(Predicted)
Farbe
Pale Brown to Light Brown
InChI
InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)
InChIKey
NBRBXGKOEOGLOI-UHFFFAOYSA-N

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 3 Einträge

H413 (100%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard]

P273, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Regulatory InformationStatus: Active Update: 08-05-2014 https://echa.europa.eu/registration-dossier/-/registered-dossier/5761
Hazard Classes and CategoriesAquatic Chronic 4 (100%)

Toxikologische Informationen

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
WGK 3
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Aquatic Chronic 4

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Protein BindingDasabuvir is greater than 99.5% bound to human plasma proteins.
PharmacodynamicsDasabuvir is classified as a direct-acting antiviral (DAA) and prevents viral replication in HCV genotype 1.
Mechanism of Action · 1 Eintrag

Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase encoded by the NS5B gene, which is essential for replication of the viral genome. Based on drug resistance mapping studies of HCV genotypes 1a and 1b, dasabuvir targets the palm domain of the NS5B polymerase, and is therefore referred to as a non-nucleoside NS5B-palm polymerase inhibitor. The EC50 values of dasabuvir against genotype 1a-H77 and 1b-Con1 strains in HCV replicon cell culture assays were 7.7 nM and 1.8 nM, respectively. By binding to NS5b outside of the active site of the enzyme, dasabuvir induces a conformational change thereby preventing further elongation of the nascent viral genome. A limitation of binding outside of the active site is that these binding sites are poorly preserved across the viral genotypes. This results in a limited potential for cross-genotypic activity and increased potential for development of resistance. Dasabuvir is therefore limited to treating genotypes 1a and 1b, and must be used in combination with other antiviral products.

Biological Half-LifeThe half-life of elimination of dasabuvir is 5.5 to 6 hours.
Metabolism/MetabolitesDasabuvir is predominantly metabolized by CYP2C8, and to a lesser extent by CYP3A.
FDA Pharmacological Classification · 6 Einträge

DE54EQW8T1

DASABUVIR

Established Pharmacologic Class [EPC] - Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor

Mechanisms of Action [MoA] - RNA Replicase Inhibitors

Mechanisms of Action [MoA] - UGT1A1 Inhibitors

Zugehörige Reaktionen

38
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 58403
HRID 58403als Produktuspto-grants-2016_09
Reaktionsgleichung von HRID 58404
HRID 58404als Produktuspto-grants-2016_09
Reaktionsgleichung von HRID 58405
HRID 58405als Produktuspto-grants-2016_09
Reaktionsgleichung von HRID 58406
HRID 58406als Produktuspto-grants-2016_09
Reaktionsgleichung von HRID 58407
HRID 58407als Produktuspto-grants-2016_09
Reaktionsgleichung von HRID 58408
HRID 58408als Produktuspto-grants-2016_09
Reaktionsgleichung von HRID 58409
HRID 58409als Produktuspto-grants-2016_09
Reaktionsgleichung von HRID 58410
HRID 58410als Produktuspto-grants-2016_09
ZurückSeite 1 von 5

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
1132935-63-7
PubChem CID
56640146
DTXSID
DTXSID301025953
ChEMBL
CHEMBL3137312
ChEBI
CHEBI:85182
UNII
DE54EQW8T1
EC Number
805-439-9
Nikkaji
J3.299.348F
SMILES
CS(NC1=CC=C2C(=C1)C=CC(C1=CC(N3C(=O)NC(=O)C=C3)=CC(C(C)(C)C)=C1OC)=C2)(=O)=O

Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors

Absorption, Distribution and Excretion · 4 Einträge

Dasabuvir reaches peak plasma concentration 4 hours after administration. The absolute bioavailability of Dasabuvir is 70%.

Dasabuvir is mainly excreted in the feces (94.4%) with very little excreted in the urine (2%). 26.2% and 0.03% of the drug excreted in the feces and urine respectively was present as the parent compound suggesting metabolism as the major elimination pathway.

Dasabuvir has a volume of distribution at steady state of 149 liters.

Clearance of Dasabuvir has not been determined.

Anwendungen

VerwendenDasabuvir is an antiviral drug used in the treatment of chronic hepatitis C virus (HCV) infection.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

1-(3-tert-Butyl-5-iodo-4-Methoxyphenyl)pyriMidin-2,4(1H,3H)-dioneN-(6-(4,4,5,5-TetraMethyl-1,3,2-dioxaborolan-2-yl)-naphthalen-2-yl)MethanesulfonaMideNatriumcarbonatTetrakis(triphenylphosphin)palladium1,4-DioxanWasser
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A member of the class of pyrimidone, which is (as the monohydrate of its sodium salt) in combination with ombitasvir, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as c rrhosis of the liver.